Company
Pharmacosmos
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
1
Approvals since 2021
2
Originals and new uses
Phase 3 trials
22
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 322
Recent approvals
Originals and efficacy supplements, newest first.
- Monoferric new use Oct 23, 2026
- Cosela approved NovelBreakthrough therapyPriority reviewFeb 12, 2021
- Monoferric approved Jan 16, 2020
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart FailurePivotal-lookingRecruiting
Pharmacosmos A/SIndustry
NCT06929806 · 1,900 participants (planned) · Start May 1, 2025 · Primary completion Dec 1, 2027
Drug: Ferric Derisomaltose · For: Chronic Heart Failure; Iron Deficiencies
Sites: Pasadena, California
- Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency AnemiaPivotal-lookingRecruiting
Pharmacosmos A/SIndustry
NCT05179226 · 200 participants (planned) · Start Nov 28, 2022 · Primary completion Apr 30, 2027
Drug: Ferric Derisomaltose · For: Iron Deficiency, Anaemia in Children
Sites: Miami, Florida
- Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung CancerPivotal-lookingRecruiting
Pharmacosmos A/SIndustry
NCT07473128 · 120 participants (planned) · Start Sep 2026 · Primary completion Oct 31, 2027
Drug: Trilaciclib; Saline (0.9% NaCl) · For: Limited Stage Small Cell Lung Cancer
Sites: Oakland, California
Marketed drugs (2)
Newest FDA action first.
- Monoferric Ferric Derisomaltose · 2020
- Cosela Trilaciclib Dihydrochloride · 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.